The invention relates to the Sbi protein of Staphylococcus aureus. It has been found that Sbi can bind to the C3 complement protein and various proteolytic fragments thereof and consequently is able to inhibit the three complement pathways (i.e. the classical pathway, the alternative pathway and the lectin pathway). The invention therefore provides methods and compositions for inhibition of the complement system and for treatment of inflammatory conditions characterised by undesirable activation of the complement pathway.
|Publication status||Published - 6 Dec 2007|